找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Hepatobiliary Cancers: An Interdisciplinary Approach; Nima Rezaei Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusi

[復(fù)制鏈接]
樓主: 鳴叫大步走
31#
發(fā)表于 2025-3-26 21:52:43 | 只看該作者
32#
發(fā)表于 2025-3-27 02:25:47 | 只看該作者
33#
發(fā)表于 2025-3-27 08:44:02 | 只看該作者
Liver Cancer and the Curative Potential of Nanomedicine,the diagnosis occurs frequently at a late stage, where treatment options are limited. Immunotherapy based on targeting checkpoint inhibitors, which unleashes the break of antitumor immunity, works only for a minority of patients. This might partly be owed to the tolerogenic function of the liver. Na
34#
發(fā)表于 2025-3-27 13:02:52 | 只看該作者
35#
發(fā)表于 2025-3-27 16:58:43 | 只看該作者
Drug Resistance in Hepatocellular Carcinoma,e acquired drug resistance increasingly affects the management of HCC patients. Researchers have focused on drug resistance for many years and identified complex regulatory networks involved in this issue. In this chapter, the significant research progress regarding mechanisms underlying HCC drug re
36#
發(fā)表于 2025-3-27 19:27:47 | 只看該作者
Liver Stereotactic Body Radiotherapy (SBRT),organs. In addition, these patients have had worse tumor outcomes when new immunotherapies have been tested in clinical trials, together suggesting there is something especially immunosuppressive about the liver tissue. Initial preclinical and translational studies have brought some light into this
37#
發(fā)表于 2025-3-28 00:17:22 | 只看該作者
38#
發(fā)表于 2025-3-28 02:40:07 | 只看該作者
39#
發(fā)表于 2025-3-28 09:16:34 | 只看該作者
40#
發(fā)表于 2025-3-28 12:43:51 | 只看該作者
Liver Cancer: Interdisciplinary Approach,nvolving multiple signaling pathways such as VEGFR, EGFR, Raf/MEK/ERK, PI3K/AKT, and Wnt. Chronic hepatitis B virus infection is the most common cause. Combining the high-risk factors, imaging features and serological molecular markers of liver cancer, biopsy or surgical resection of liver space-occ
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 19:55
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
易门县| 芜湖市| 迭部县| 大名县| 韶山市| 柯坪县| 潢川县| 南充市| 太仓市| 梧州市| 平安县| 休宁县| 龙门县| 崇信县| 霸州市| 邳州市| 广水市| 洛隆县| 礼泉县| 青浦区| 正阳县| 五家渠市| 揭西县| 东城区| 东海县| 大悟县| 乐昌市| 南澳县| 宁乡县| 临沭县| 遂宁市| 临泽县| 城口县| 闽清县| 明溪县| 平阴县| 南城县| 建阳市| 彭阳县| 蓬安县| 辽宁省|